Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.

Goal 2: Reduce Human Disease

Promoting Physical Activity in COPD

The GOLD guidelines recommend regular physical activity in all patients with stable COPD. How we operationalize this is completely unclear. We know pulmonary rehab works but few patients are referred and fewer participate. We also know physical activity, not just exercise, directly measured in the field is associated with COPD-specific outcomes such as acute exacerbations, hospitalizations and death. How do we bring ...more »

Submitted by (@marilynmoy)

Voting

4 net votes
5 up votes
1 down votes
Active

Goal 2: Reduce Human Disease

Support for Cardiothoracic Surgery and Pediatric Heart Clinical Trial Networks

Continued and expanded support for the Cardiothoracic Surgical Trials Network (CTSN) and Pediatric Heart Network (PHN) is essential as both design, conduct, and analyze multiple, collaborative clinical trials that evaluate surgical interventions, and related management approaches for the treatment of cardiovascular disease. To date both networks have reported on and developed a portfolio of studies which need continued ...more »

Submitted by (@meaton)

Voting

108 net votes
151 up votes
43 down votes
Active

Goal 2: Reduce Human Disease

Need to assess a new method of warfarin management vs. new oral anticoagulants in patients with atrial fibrillation

The two obstacles to warfarin therapy (keeping the INR in range and the associated hassles of frequent lab visits) can be eliminated by INR self testing and online "virtual clinic" monitoring and management (as demonstrated in six small studies. Achieving an INR percent time in range of approximately 75% to 80% is associated with a 50% or lower rate of thromboembolism and major bleeding. The studies of new oral anticoagulants ...more »

Submitted by (@bussey)

Voting

73 net votes
93 up votes
20 down votes
Active

Goal 2: Reduce Human Disease

Would patients with pulmonary arterial hypertension (PAH) benefit from background anticoagulation in addition to their PAH-targe

Pulmonary hypertension (PH) is a complex, progressive condition characterized by high blood pressure in the lungs. For several decades, oral anticoagulation has been recommended by some societies for patients with a specific form of PH called pulmonary arterial hypertension. However, the evidence currently supporting this recommendation is very limited. To date, no prospective randomized clinical trial has been completed ...more »

Submitted by (@katherinek)

Voting

62 net votes
68 up votes
6 down votes
Active

Goal 2: Reduce Human Disease

What is the optimal process for terminal withdrawal of mechanical ventilation?

This palliative care process permits a natural death. The process is largely unstandardized and reflects local practice customs. In fact, the process may vary across ICUs and even within an ICU based on whose attending the patient. This process continues to be an under-investigated area of ICU care for terminally ill patients undergoing terminal ventilator withdrawal.

Submitted by (@megcampbell)

Voting

1 net vote
7 up votes
6 down votes
Active